News

Provenge is a patient specific therapeutic cancer vaccine for prostate cancer (CaP). Dendreon, which expects to receive a European approval for the product’s marketing authorisation application (MAA) by

Vinton Healthcare owned a manufacturing unit and also partly owned Wockhardt‘s nutrition business along with two other subsidiaries – Wockhardt EU Operations (Swiss) and Carol Info Service, which

Most recently, Lundstrom worked as the head of Biogen Idec International Commercial Operations, and was responsible for sales and marketing in 28 countries and through distributors in over

Biogen Idec aims to cash in on the major role that biosimilars will play in health care in the near future. According to a US Congressional Budget Office

The milestone was reached on the transition of an oncology programme into lead optimisation. The collaboration was made for jointly indentifying and developing preclinical development candidates for the

MEDI-565 (MT111) is a BiTE antibody designed to direct a patient’s T cells, the body’s most potent killer cells, against cancer cells that express carcinoembryonic antigen (CEA). The

The collaboration will enable more patients to participate in trials of potential new cancer treatments that combine molecularly targeted experimental drugs developed and owned by AstraZeneca. The trials

GSK and ChemoCentryx said that the study will assess the efficacy and safety of ‘786 for inducing a response and remission (reduction or disappearance of symptoms) and maintaining

Under the agreement DSM Pharmaceutical can use Codexis’ custom biocatalysts and services, and secures supply of Codexis enzymes for commercialization of sustainable enzyme-based pharmaceutical manufacturing routes developed by